[
  {
    "ts": null,
    "headline": "Biogen Pipeline Advances In Lupus And SMA Reshape Growth Outlook",
    "summary": "Biogen (NasdaqGS:BIIB) received Breakthrough Therapy Designation from the FDA for litifilimab in cutaneous lupus erythematosus. The company reported phase 2/3 trial results for high dose nusinersen in spinal muscular atrophy. Both updates relate to Biogen's drug pipeline in neurological and autoimmune diseases. For investors watching Biogen, these updates go to the heart of what drives the company: its drug pipeline. Biogen is known for treatments targeting neurological and related...",
    "url": "https://finnhub.io/api/news?id=64ad7655c781dab2b5aea2f8e53395df8b314dfc0a1d24a6061beaeda8c5b9f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770725346,
      "headline": "Biogen Pipeline Advances In Lupus And SMA Reshape Growth Outlook",
      "id": 139029958,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (NasdaqGS:BIIB) received Breakthrough Therapy Designation from the FDA for litifilimab in cutaneous lupus erythematosus. The company reported phase 2/3 trial results for high dose nusinersen in spinal muscular atrophy. Both updates relate to Biogen's drug pipeline in neurological and autoimmune diseases. For investors watching Biogen, these updates go to the heart of what drives the company: its drug pipeline. Biogen is known for treatments targeting neurological and related...",
      "url": "https://finnhub.io/api/news?id=64ad7655c781dab2b5aea2f8e53395df8b314dfc0a1d24a6061beaeda8c5b9f0"
    }
  },
  {
    "ts": null,
    "headline": "Why Biogen (BIIB) Is Up 8.2% After Mixed 2025 Earnings and Neurology Pipeline Updates – And What's Next",
    "summary": "Biogen recently reported fourth-quarter and full-year 2025 results showing quarterly sales of US$521.2 million and revenue of US$2.28 billion, but a quarterly net loss of US$48.9 million contrasted with a strong full-year net income of US$1.29 billion. Alongside earnings, Biogen highlighted progress in its neurology pipeline, including FDA Breakthrough Therapy Designation for litifilimab in cutaneous lupus and ongoing review of a high-dose SPINRAZA regimen for spinal muscular atrophy. Next,...",
    "url": "https://finnhub.io/api/news?id=ca3558c3d2fb01ceceb0b706a6943b88ba5a785b706ca9a5c78e761a642c31af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770703574,
      "headline": "Why Biogen (BIIB) Is Up 8.2% After Mixed 2025 Earnings and Neurology Pipeline Updates – And What's Next",
      "id": 139027222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen recently reported fourth-quarter and full-year 2025 results showing quarterly sales of US$521.2 million and revenue of US$2.28 billion, but a quarterly net loss of US$48.9 million contrasted with a strong full-year net income of US$1.29 billion. Alongside earnings, Biogen highlighted progress in its neurology pipeline, including FDA Breakthrough Therapy Designation for litifilimab in cutaneous lupus and ongoing review of a high-dose SPINRAZA regimen for spinal muscular atrophy. Next,...",
      "url": "https://finnhub.io/api/news?id=ca3558c3d2fb01ceceb0b706a6943b88ba5a785b706ca9a5c78e761a642c31af"
    }
  }
]